A phase II study to evaluate the safety and immunological efficacy of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with HER2 expressing gastric cancer (CORNERSTONE-003, NCT05771584)

AST-301 - University of Washington, Aston Sci., EpiThany

S. Luo1; L. Bai2; I. Wu3; N. Kang4; M. Chen5; W. Chou6; M. HUANG7; H. Jung7; W. Kim7

Oct 4, 2025